Search Results 151-160 of 38086 for Two-phase

1. Neurology - Clinical trials

   To accomplish this aim CREST-H will add on to the NINDS-sponsored CREST-2 trial (parallel, outcome-blinded Phase ... stage (PAF), and even at a prodromal stage ( ...

2. Exercise and Low-Dose Rapamycin in Older Adults with CAD:Cardiac Rehabilitation And Rapamycin in Elderly (CARE) Trial - Mayo Clinic

   The investigators will do the study in two phases. ... If favorable changes are noted in the SASP or AAI, the investigators will start a phase 2 randomized trial.

3. New treatment option for early type 1 diabetes - Mayo Clinic

   ... stages: Stage 1: two or more positive diabetes autoantibodies but normal blood glucose levels. Stage 2: two or more positive diabetes autoantibodies and ...

4. Neurology - Clinical trials - Mayo Clinic

   The purpose of phase 2 of this trial is to evaluate the effectiveness of sequentially administering temozolomide and selinexor in recurrent glioblastoma as ...

5. TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) - Mayo Clinic

   TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell ...

6. A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis - Mayo Clinic

   About this study. The purpose of trhis study is to evaluate CPI-0610 in patients who have both received JAK inhibitors, such as ruxolitinib (Arms 1 and 2), ...

7. Hodgkin lymphoma (Hodgkin disease) - Stages - Mayo Clinic

   A stage 2 Hodgkin lymphoma involves two or more lymph node regions on the same side of the diaphragm. Stage 3 lymphoma. At stage 3, Hodgkin lymphoma ...

8. A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD - Mayo Clinic

   Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines ...

9. A Phase 2 Trial Of ALN-APP In Patients With Cerebral Amyloid Angiopathy - Mayo Clinic

   The study will be conducted over 2 periods: a 24-month double-blind treatment period and an optional 18-month open-label extension (OLE) period. The estimated ...

10. A Randomized, Placebo-controlled, Double-blind, Multi-center Phase 2/3 Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients with Symptomatic Polycystic Liver Disease - Mayo Clinic

    A Randomized, Placebo-controlled, Double-blind, Multi-center Phase 2/3 Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in ...